Immune-Onc Therapeutics Discloses a Partnership for Clinical Research, Assessing IO-108 in an International Early Phase Trial Aimed at Initial Therapy for Progressive Hepatic Carcinoma.

Monopar Approved to Initiate Initial Human Stage 1 Study of Experimental Radiotherapeutic MNPR-101-Zr for Progressive Cancer Cases.

The FDA has granted Mabwell authorization to proceed with their new ADC targeting B7-H3, referred to as 7MW3711 under an Investigational New Drug application.

Iterion Therapeutics stated that initial dosing has commenced in an early to mid-stage study of their drug Tegavivint for advanced liver cancer cases unresponsive to previous systemic therapies.

Teva Pharmaceuticals has released encouraging initial results concerning the safety, patient tolerance, and pharmacokinetic profile of its investigational product known as anti-TL1A (TEV-’574).

NextPoint Therapeutics Reveals Initiation of Early-Stage Clinical Study with First Subject Receiving NPX887 for Solid Tumors Containing HHLA2, an Innovative Treatment Aiming to Revitalize Worn-Out T and NK Cells.

argenx has reported that the FDA has granted priority review status for their updated biologics application for VYVGART Hytrulo, aimed at treating chronic inflammatory demyelinating polyneuropathy.

Arvinas Reports Initial Human Administration of Experimental PROTAC® Compound ARV-102 for Neurological Disorders Treatment.

Philogen Announces Preliminary Results from Phase III FIBROSARC Study Evaluating Onfekafusp alfa (L19TNF) in Initial Treatment of Advanced or Metastatic Soft Tissue Sarcoma.

Innovent Reveals Key Goal Achieved in Phase 3 Study (RESTORE-1) of IBI311 (IGF-1R-Targeting Agent) for Thyroid Eye Condition, Intends to File for Approval with NMPA.

Bayer commences a second-stage trial using a novel anti-alpha2 antiplasmin agent in individuals affected by deep venous clots.

EU Regulatory Body Sanctions Pfizer's VELSIPITY® Use in Individuals with Moderate to Severe Ulcerative Colitis Cases.